骨质疏松与一氧化氮

一氧化氮 (ｎｉｔｒｉｃｏｘｉｄｅ ,ＮＯ)极易透过生物膜 ,是细胞间、细胞内的信使分子 ,其扩散速度、穿透细胞膜的能力、内在不稳定性等特征极为显著。由于其合成易于调节 ,作为高级生物体调节的有效信号在循环、呼吸、消化及内分泌代谢等系统中发挥着重要影响。近年来发现ＮＯ及其一氧化氮合酶 (ｎｉｔｒｉｃｏｘ ｉｄｅｓｙｎｔｈａｓｅ ,ＮＯＳ)在参与和促进骨质疏松症 (ｏｓｔｅｏ ｐｏｒｏｓｉｓ ,ＯＰ)病理生理过程中也占有举足轻重的作用。1　ＮＯ、ＮＯＳ合成与代谢通过免疫组化及更灵敏的逆转录酶聚合酶链反应 (ＲＴ -ＰＣＲ) ,…     

Evidence for a detrimental role of nitric oxide synthesized by endothelial nitric oxide synthase after peripheral nerve injury

Physical injury to a nerve is the most common cause of acquired peripheral neuropathy. Identification of molecules involved in degenerative and regenerative processes is a key step toward development of therapeutic tools in order to accelerate motor, sensory and/or autonomic function recovery. We have studied the role of nitric oxide (NO) using as a model the severe crushing of a motor nerve in adult rats. This type of injury up-regulates the three isoforms of nitric oxide synthase (NOS) in the affected nerve. Chronic systemic inhibition of NOS accelerated the onset of functional muscle reinnervation evaluated by the recording of compound muscle action potential evoked by electrical stimulation of the injured nerve. Besides, it increased the number of back-labeled motoneurons by application, 2 days after injury, of a retrograde marker 10 mm distal to the crushing site. These effects were mimicked by chronic specific inhibition of the endothelial isoform of nitric oxide synthase (eNOS), but not by specific inhibitors of the neuronal or inducible isoform. Next, we intraneurally injected a replication-deficient adenoviral vector directing the expression of a dominant negative mutant of eNOS (Ad-TeNOS). A single injection of Ad-TeNOS on the day of crushing significantly accelerated functional recovery of neuromuscular junction and increased axonal regeneration. Moreover, Ad-TeNOS did not compromise motoneuron viability or stability of reestablished neuromuscular junctions. Taken together, these results suggest that NO of endothelial origin slows down muscle reinnervation by means of detrimental actions on axonal regeneration after peripheral nerve injury. These experiments identify eNOS as a potential therapeutic target for treatment of traumatic nerve injuries and highlight the potential of gene therapy in treating injuries of this type using viral vectors to suppress the activity of eNOS.     

Involvement of endogenous nitric oxide in the regulation of K+ channel activity in cultured human proximal tubule cells

Nitric oxide (NO) modulates the activity of an inwardly rectifying K(+) channel in cultured human proximal tubule cells. In this study, we investigated which NO synthase (NOS) isoform(s) was involved in the endogenous production of NO and hence the regulation of channel activity. The patch-clamp experiments using the cell-attached mode showed that a nonselective NOS inhibitor, N(omega)-nitro-L-arginine methyl ester (L-NAME; 100 microM), suppressed channel activity, whereas a NOS substrate, L-arginine (500 microM), stimulated it. A neuronal NOS (nNOS)/inducible NOS (iNOS)-selective inhibitor, 1-(alpha,alpha,alpha-trifluoro-o-tolyl)-imidazole (TRIM; 100 microM), suppressed channel activity to the same extent as L-NAME. TRIM also blocked the stimulatory effect of L-arginine. In contrast, an NO donor, sodium nitroprusside (10 microM) or 8-bromoguanosine 3',5'-cyclic monophosphate (100 microM) stimulated channel activity even in the presence of TRIM. RT-PCR revealed that iNOS mRNA alone was expressed in most of the cultures, i.e., 34 out of 40. In the other 6 cases, endothelial NOS (eNOS) and iNOS mRNA were simultaneously expressed. This finding was confirmed at the protein level by Western blotting. Indeed, in the patch-clamp experiments TRIM sometimes failed to suppress the channel activity, but the following addition of L-NAME suppressed it. However, since the suppressive effect of TRIM was usually similar to that of L-NAME, the involvement of eNOS in K(+) channel regulation would be relatively low. These results suggest that iNOS plays a pivotal role in the endogenous production of NO under the basal condition, which is involved in the activity of the inwardly rectifying K(+) channel in cultured human proximal tubule cells.     

mRNA and protein expression and activities of nitric oxide synthases in the lumbar spinal cord of neonatal rats after sciatic nerve transection and melatonin administration

Sciatic axotomy in 2-day-old rats (P2) causes lumbar motoneuron loss, which could be associated with nitric oxide (NO) production. NO may be produced by three isoforms of synthase (NOS): neuronal (nNOS), endothelial (eNOS) and inducible (iNOS). We investigated NOS expression and NO synthesis in the lumbar enlargement of rats after sciatic nerve transection at P2 and treatment with the antioxidant melatonin (sc; 1 mg/kg). At time points ranging from P2 to P7, expression of each isoform was assessed by RT-PCR and immunohistochemistry; catalytic rates of calcium-dependent (nNOS, eNOS) and independent (iNOS) NOS were measured by the conversion of [3H]L-arginine to [3H]L-citrulline. All NOS isoforms were expressed and active in unlesioned animals. nNOS and iNOS were detected in some small cells in the parenchyma. Only endothelial cells were positive for eNOS. No NOS isoform was detected in motoneurons. Axotomy did not change these immunohistochemical findings, nNOS and iNOS mRNA expression and calcium-independent activity at all survival times. However, sciatic nerve transection reduced eNOS mRNA levels at P7 and increased calcium-dependent activity at 1 and 6 h. Melatonin did not alter NOS expression. Despite having no action on NOS activity in unlesioned controls the neurohormone enhanced calcium-dependent activity at 1 and 72 h and reduced calcium-independent catalysis at 72 h in lesioned rats. These results suggest that NOS isoforms are constitutive in the neonatal lumbar enlargement and are not overexpressed after sciatic axotomy. Changes in NO synthesis induced by axotomy and melatonin administration in the current model are discussed considering some beneficial and deleterious effects that NO may have.     

Trafficking and activation of eNOS in epithelial cells

In mammalian cells, formation of nitric oxide (NO) is catalysed by a family of enzymes termed NO synthases (NOS). There are three isoforms of this enzyme, NOS I, II and III. NOS III was originally cloned and identified in endothelial cells; thus this isoform is commonly called endothelial NOS (eNOS). The physiological role of NO produced by eNOS has been documented in most organs, including the brain, lung, cardiovascular system, kidney, liver, gastrointestinal tract and reproductive organs. The bioavailability of NO in these tissues is determined by the balance between its rate of production and degradation. The rate of NO production by eNOS is ultimately dependent on the activity of the enzyme. In the past years, co- and post-translational modifications such as myristoylation, palmitoylation, phosphorylation, protein-protein interactions and subcellular localization have been shown to play an important role in determining eNOS activity. In order to maintain specificity, the production of most signalling molecules occurs in an organized spatial and temporal pattern. Spatial localization of eNOS has been shown to be regulated by different mechanisms that control its targeting from the Golgi apparatus to the plasma membrane, correct compartmentalization within the membrane, and internalization from the plasma membrane to the cytoplasm after activation. Thus, regulated localization and trafficking of eNOS may be essential in regulating enzyme activity and maintaining the spatial and temporal organization of NO signalling in different cell types.     

Anti-sclerostin antibodies: Utility in treatment of osteoporosis

Monoclonal antibodies to molecular targets important for bone formation and bone resorption are being investigated for treatment of postmenopausal osteoporosis. Postmenopausal osteoporosis is characterized by increased bone turnover, with bone resorption typically exceeding bone formation. These pathophysiological changes cause decreased bone mineral density and disruption of bone microarchitecture which lead to low-trauma fractures.     

Protective role of endothelial nitric oxide synthase

Nitric oxide is a versatile molecule, with its actions ranging from haemodynamic regulation to anti-proliferative effects on vascular smooth muscle cells. Nitric oxide is produced by the nitric oxide synthases, endothelial NOS (eNOS), neural NOS (nNOS), and inducible NOS (iNOS). Constitutively expressed eNOS produces low concentrations of NO, which is necessary for a good endothelial function and integrity. Endothelial derived NO is often seen as a protective agent in a variety of diseases.This review will focus on the potential protective role of eNOS. We will discuss recent data derived from studies in eNOS knockout mice and other experimental models. Furthermore, the role of eNOS in human diseases is described and possible therapeutic intervention strategies will be discussed.     

内皮型一氧化氮合酶基因转染对人吞噬细胞释放细胞因子和生成环核苷酸的影响

目的和方法:将内皮型一氧化氮合酶基因转染吞噬细胞,观察该基因表达对吞噬细胞释放细胞因子和cAMP的影响。 结果:内皮型一氧化氮合酶可在吞噬细胞获得稳定表达,但该产物在活细胞中不产生一氧化氮。一氧化氮合酶基因表达可上调TNF-α的释放,下调IL-10和cAMP的生成,使用一氧化氮合酶抑制剂不改变这种变化趋势。结论:内皮型一氧化氮合酶基因产物的功能具有细胞特异性。导致吞噬细胞功能变化的效应分子可能不是一氧化氮。     

Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity

Nitric oxide (NO) has been implicated in the local regulation of bone metabolism. However, the contribution made by specific NO synthase (NOS) enzymes is unclear. Here we show that endothelial NOS gene knockout mice (eNOS-/-) have marked abnormalities in bone formation. Histomorphometric analysis of eNOS-/- femurs showed bone volume and bone formation rate was reduced by up to 45% (P: < 0.01) and 52% (P: < 0.01), respectively. These abnormalities were prevalent in young (6 to 9 weeks old) adults but by 12 to 18 weeks bone phenotype was restored toward wild-type. Dual energy X-ray absorptiometry analysis confirmed the age-related bone abnormalities revealing significant reductions in femoral (P: < 0.05) and spinal bone mineral densities (P: < 0.01) at 8 weeks that were normalized at 12 weeks. Reduction in bone formation and volume was not related to increased osteoclast numbers or activity but rather to dysfunctional osteoblasts. Osteoblast numbers and mineralizing activity were reduced in eNOS-/- mice. In vitro, osteoblasts from calvarial explants showed retarded proliferation and differentiation (alkaline phosphatase activity and mineral deposition) that could be restored by exogenous administration of a NO donor. These cells were also unresponsive to 17ss-estradiol and had an attenuated chemotactic response to transforming growth factor-beta. In conclusion, eNOS is involved in the postnatal regulation of bone mass and lack of eNOS gene results in reduced bone formation and volume and this is related to impaired osteoblast function.     

Impairment of neocortical long-term potentiation in mice deficient of endothelial nitric oxide synthase

The role of the possible retrograde messenger nitric oxide (NO) in the induction of long-term potentiation (LTP) was studied in supragranular layers of somatosensory cortical slices obtained from adult mice. High-frequency stimulation produced a slowly rising, long-lasting (50 min) and significant (P < 0.001) increase in the extracellular synaptic response by 23%. The induction of LTP was independent from activation of N-methyl-D-aspartate (NMDA) receptors, but prevented by bath application of NG-nitro-L-arginine methyl ester (L-NAME), indicating that one or several of the different NO synthases (NOS) produced NO within the postsynaptic neuron. No LTP could be induced in knockout mice lacking the endothelial NOS (eNOS) isoform. These data suggest that eNOS is involved in an NMDA receptor-independent form of LTP in the rodent cerebral cortex.     

Inducible and endothelial nitric oxide synthase expression during development of transplant arteriosclerosis in rat aortic grafts.

In the vascular system, distinct isoforms of nitric oxide synthase (NOS) generate nitric oxide (NO), which acts as a biological messenger. Its role in the development of transplant arteriosclerosis (TA) is still unclear. To investigate whether NO is involved in TA, we studied the expression of NOS isoforms, inducible NOS (iNOS) and endothelial NOS (eNOS), by immunohistochemistry and in situ hybridization during the first two post-transplantation months and their relation with cold ischemia (1 to 24 hours) and reperfusion injury using an aortic transplantation model in the rat. We found an increased iNOS expression in the intima and adventitia and a decreased expression in the media, whereas eNOS expression was not significantly altered during the development of TA. Co-localization studies suggested that iNOS-positive cells were vascular smooth muscle cells, monocyte-derived macrophages, and endothelial cells. Prolonged ischemic storage time resulted in an increase in eNOS expression in the neointima. In situ hybridization showed iNOS mRNA expression by vascular cells in the neointima and media. NO produced by iNOS and eNOS may be involved, at least in part, in the pathogenesis of TA in aortic grafts. Additional studies are needed to confirm the modulatory mechanism of NO during the development of TA.     

Role of nitric oxide in implantation and menstruation

Nitric oxide (NO) is a major paracrine mediator of various biological processes, including vascular functions and inflammation. In blood vessels, NO is produced by the low-input constitutive endothelial NO synthase (eNOS) and is a potent vasodilator and platelet aggregation inhibitor. The inducible NOS isoform (iNOS) is capable of producing NO at high concentrations which have pro-inflammatory properties. Immunohistochemical and molecular studies of endometrial NOS expression, as well as animal experiments with NOS inhibitors, indicate that NO plays an important role in endometrial functions such as endometrial receptivity, implantation and menstruation. In rodents, both iNOS and eNOS are highly up-regulated in the implantation sites, and NOS inhibitors show synergistic effects with antiprogestins in inhibiting the establishment of pregnancy. In the human endometrium, eNOS have been localized in the glandular epithelium and in endometrial microvascular endothelium, primarily during the luteal phase. iNOS has been found in the endometrial epithelium during menstruation, in immunocompetent endometrial cells, and in decidualized stromal cells. In primates, NO may be involved in the initiation and maintenance of menstrual bleeding by inducing tissue breakdown and vascular relaxation as well as by inhibiting platelet aggregation. Endometrium-derived NO may also play a role in myometrial relaxation during menstruation. These studies open up new applications for NO-donating and -inhibiting agents in uterine disorders. NO donors may be useful in the treatment of dysmenorrhoea and for promoting fertility. Antiprogestins, progesterone receptor modulators and iNOS inhibitors may find applications in the treatment and prevention of abnormal uterine bleeding.     

Intra- and inter-hemispheric coupling of electroencephalographic 8-13 Hz rhythm in humans and force of static finger extension

Information on equipment and subcellular distribution of nitric oxide synthase (NOS) isoforms in myenteric neurons and pacemaker cells (ICC) might help to identify nitric oxide (NO) pathway(s) acting on gastrointestinal motility. In sections of mouse colon labelled with neuronal (n)NOS, endothelial (e)NOS and inducible (i)NOS antibodies, all myenteric neurons co-expressed eNOS and iNOS and a subpopulation of them co-expressed nNOS. ICC co-expressed nNOS and eNOS. In the neurons, nNOS-labeling was intracytoplasmatic, in the ICC at cell periphery. In both cell types, eNOS-labeling was on intracytoplasmatic granules, likely mitochondria. In conclusion, myenteric neurons and ICC co-express several NOS isoforms with specific subcellular distribution. Different nNOS splice variants are presumably present: intracytoplasmatic nNOSbeta and nNOSalpha producing neurogenic NO, plasma membrane-bound nNOSalpha producing ICCgenic NO. eNOS might be implicated in mitochondrial respiration and, in ICC, also in pacemaker activity. Neurons express iNOS also in basal condition.     

Endothelial nitric oxide synthase gene polymorphism is associated with Behçet's disease in Tunisian population

Nitric oxide (NO) is a molecule that plays a key role in many physiologic and pathologic processes. It is produced in vivo from the aminoacid l-arginine by a family of nitric oxide synthases (NOS). Endothelial NOS (eNOS) is a constitutively expressed isoform of NOS. The eNOS gene entails several polymorphisms, of which certain were investigated in Beh?et's disease (BD). We sought to establish the association of eNOS gene Glu298Asp polymorphism in exon 7 with susceptibility to BD. In this study, 135 Tunisian patients with BD and 157 healthy blood donor controls from the same geographic area were genotyped by polymerase chain reaction technique for eNOS polymorphism in exon 7. Our results showed that the distribution of the Glu298Asp genotype differed between BD patients and controls but did not reach statistical significance (p = 0.06). Allele Asp298 was significantly more frequent in healthy controls than in BD patients (p = 0.037, chi(2) = 4.33, OR = 1.01, 95% CI = 1.41-1.99). A significant difference was found (p = 0.004, OR = 1.26, 95% CI = 2.13-3.62) between BD patients with skin lesions and patients without this manifestation. Our findings suggest that Glu298Asp polymorphism of eNOS gene is associated with BD susceptibility as well as skin lesions.     

The role of nitric oxide in innate immunity

Summary: Type 2 nitric oxide synthase (iNOS or NOS2) was originally described as an enzyme that is expressed in activated macrophages, generates nitric oxide (NO) from the amino acid l-arginine, and thereby contributes to the control of replication or killing of intracellular microbial pathogens. Since interferon (IFN)-g is the key cytokine for the induction of NOS2 in macrophages and the prototypic product of type 1 T-helper cells, high-level expression of NOS2 has been regarded to be mostly restricted to the adaptive phase of the immune response. In this review, we summarize data that demonstrate a prominent role of NOS2/NO also during innate immunity. During the early phase of infection with the intra­cellular pathogen Leishmania major , focally expressed NOS2/NO not only exerts antimicrobial activities but also controls the function of natural killer cells and the expression of cytokines such as IFN-g or transforming growth factor-b. Some of these effects result from the function of NOS2/NO as an indispensable co-factor for the activation of Tyk2 kinase and, thus, for interleukin-12 and IFN-a/b signaling in natural killer cells.     

Ovary and ovulation: Cell-specific localization of nitric oxide synthases (NOS) in the rat ovary during follicular development, ovulation and luteal formation

Nitric oxide (NO) has emerged as one of several important intraovarianregulatory factors. In particular, NO has been implicated inthe processes of ovulation and atresia-related apoptosis. Theaim of the present study was to investigate the presence anddistribution of the NO-generating nitric oxide synthase (NOS)enzymes in the ovary during follicular development, ovulationand luteal formation of the equine chorionic gonadotrophin (ECG)/humanchorionic gonado-trophin (HCG)-primed rat NADPH diaphorase activitywas used as a histochemical marker for NOS within the ovary.Diaphorase reactivity was most abundant in the stroma (S) ofthe ovary and in the theca (T) layer of the follicle. In luteinizedovaries, weaker diaphorase reactivity was present within thecorpora lutea (CL). Two different isoforms of NOS, the constitutivelyexpressed endothelial NOS (eNOS) and the inducible isoform ofNOS (iNOS), were immunolocalized in ovaries of immature ratsand in ECG/HCG-primed rats during the periovulatory period fromHCG injection until 2 days after ovulation. In addition, ovarianconcentrations of eNOS and iNOS were quantified by immunoblotting.Immunoblotting with a monoclonal anti-eNOS antibody demonstratedthe presence of eNOS mainly in the residual ovary (ROV) duringthe periovulatory period. In luteinized ovaries, higher concentrationsof eNOS were seen in CL, while those in the ROV at this stagewere lower than in the periovulatory ovary. Immature ovariescontained diminutive amounts of eNOS, detectable mostly in theROV compartment. In contrast, iNOS was barely detectable duringfollicular development to the preovulatory stage. A slight elevationof iNOS was observed in the granulosa cells at 6 h after theHCG injection. The levels of iNOS during the luteal phase werealso low. Immunohistochemical analysis using polyclonal eNOSand iNOS antibodies revealed the localization of these two isoformsprimarily in the S and the T of the periovulatory ovary. Inluteinized ovaries, positive immunoreactivity was also seenwithin the CL. With a monoclonal antibody against eNOS, intenseimmunoreactivity was observed in the S, T and within CL. Therewas a particularly strong staining in blood vessels. These datademonstrate the presence of an intraovarian NO-generating system.The localization of this system to the S, T and CL suggestsa role for NO in the ovulatory process and in the regulationof CL function.     

Non-lethal Sepsis and Nitric Oxide Inhibition in the Guinea Pig

Nitric oxide (NO) is synthesized from arginine by three distinct isoforms of nitric oxide synthase (NOS). Two of these isoforms, endothelial NOS (eNOS, type III NOS) and neuronal NOS (nNOS, type I NOS) are expressed in a constitutive manner and are responsible for regulating physiological functions. The induction of the third isoform of nitric oxide synthase (iNOS) by inflammatory processes and the subsequent overproduction of NO is thought to contribute to the tissue damage that occurs in a number of diseases having an inflammatory component, such as sepsis. As a model of sepsis, non-lethal endotoxemia in Hartley guinea pigs was induced using three serotypes of lipopolysaccharide (LPS, 30 mg/kg, i.p.). Each stimulated an increase in total plasma nitrites 6 h following their administration. Treatment orally with two inhibitors of NOS, L-nitroarginine methyl ester (L-NAME), a non-selective inhibitor and N-iminoethyl-L-lysine (L-NIL), a selective iNOS inhibitor, 30 min after the induction of sepsis, inhibited (p < 0.05) the increase in plasma nitrites with ED₅₀ values of 7 ± 1 and 0.4 ± 0.03 mg/kg, respectively, suggesting that NOS inhibitors may be useful in the treatment of human sepsis, or other diseases where excess NO levels have been implicated, such as asthma, arthritis and inflammatory bowel disease.     

Regional variations and age-related changes in nitric oxide synthase and arginase in the sub-regions of the hippocampus

L-arginine can be metabolised by nitric oxide synthase (NOS) with the formation of L-citrulline and nitric oxide (NO), or arginase with the production of L-ornithine and urea. In contrast to studies showing a potential involvement of NOS/NO in the aging process, the role of arginase has not been well documented. The present study investigates for the first time the regional variations and age-related changes in both NOS and arginase in sub-regions of the hippocampus. In young adult rats, although the total NOS activity was not significantly different across the hippocampal CA1, CA2/3 and the dentate gyrus (DG) sub-regions, the total arginase activity showed a clear regional variation with the highest level in DG. Western blotting revealed that the highest levels of neuronal NOS (nNOS) and endothelial NOS (eNOS) proteins were located in CA1. Arginase I is expressed at a very low level in the brain (the whole hippocampus) as compared with the liver. By contrast, arginase II protein shows an extremely high expression in the brain with little or no expression in the liver. There was no regional variation in arginase I or arginase II protein expression across the sub-regions of the hippocampus. When a comparison was made between young (4-month-old) and aged (24-month-old) rats, a significant increase in total NOS activity was found in DG and significant decreases in arginase activity were observed in the CA1 and CA2/3 regions in the aged animals. Western blotting further revealed a dramatic decrease in eNOS protein expression in aged CA2/3 with no age-associated changes in nNOS, arginase I and II protein expression in any region examined. Interestingly, evidence of activity or protein expression of the inducible isoform of NOS (iNOS) was not detected in any tissue from either group. The present results, in conjunction with previous findings, support the contribution of NOS/NO to aging but question the involvement of iNOS in the normal aging process. Region-specific changes in arginase suggest that this enzyme may also contribute to aging.